Duopharma Biotech Bhd. Statistics
Duopharma Biotech Bhd. (7148) Stock Statistics & Valuation Metrics
Total Valuation
Duopharma Biotech Bhd. has a market cap or net worth of MYR 1.03B. The enterprise value is MYR 1.36B.
- Market Cap
- MYR 1.03B
- Enterprise Value
- MYR 1.36B
Share Statistics
Duopharma Biotech Bhd. has 961,942,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 961,942,440
- Owned by Insiders
- ―
- Owned by Institutions
- 0.09%
Financial Efficiency
Duopharma Biotech Bhd.’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.70%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.06
- Return on Invested Capital (ROIC)
- 8.70%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 465.61K
- Profits Per Employee
- 43.71K
- Employee Count
- 2,001
- Asset Turnover
- 0.64
- Inventory Turnover
- 1.94
Valuation Ratios
The current PE Ratio of Duopharma Biotech Bhd. is 10.08. Duopharma Biotech Bhd.’s PEG ratio is 0.26.
- PE Ratio
- 10.08
- PS Ratio
- 1.11
- PB Ratio
- 1.31
- Price to FCF
- 15.00
- Price to Operating Cash Flow
- 11.79
- PEG Ratio
- 0.26
Income Statement
In the last 12 months, Duopharma Biotech Bhd. had revenue of 931.69M and earned 87.46M in profits. Earnings per share was 0.09.
- Revenue
- 931.69M
- Gross Profit
- 363.14M
- Operating Income
- 146.49M
- Pretax Income
- 114.91M
- Net Income
- 87.46M
- EBITDA
- 192.11M
- Earnings Per Share (EPS)
- 0.09
Cash Flow
In the last 12 months, operating cash flow was 87.31M and capital expenditures -18.70M, giving a free cash flow of 68.61M billion.
- Operating Cash Flow
- 87.31M
- Free Cash Flow
- 68.61M
- Free Cash Flow per Share
- 0.07
Dividends & Yields
Duopharma Biotech Bhd. pays an annual dividend of ―, resulting in a dividend yield of 4.25%
- Dividend Per Share
- ―
- Dividend Yield
- 4.25%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.48%
- Earnings Yield
- 9.66%
Stock Price Statistics
- Beta
- 0.58
- 52-Week Price Change
- -15.75%
- 50-Day Moving Average
- 1.16
- 200-Day Moving Average
- 1.25
- Relative Strength Index (RSI)
- 38.16
- Average Volume (3m)
- 360.90K
Important Dates
Duopharma Biotech Bhd. upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 18, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Duopharma Biotech Bhd. as a current ratio of 2.61, with Debt / Equity ratio of 65.06%
- Current Ratio
- 2.61
- Quick Ratio
- 1.68
- Debt to Market Cap
- 0.41
- Net Debt to EBITDA
- 1.05
- Interest Coverage Ratio
- 5.92
Taxes
In the past 12 months, Duopharma Biotech Bhd. has paid 27.45M in taxes.
- Income Tax
- 27.45M
- Effective Tax Rate
- 0.24
Enterprise Valuation
Duopharma Biotech Bhd. EV to EBITDA ratio is 6.06, with an EV/FCF ratio of 18.56.
- EV to Sales
- 1.37
- EV to EBITDA
- 6.06
- EV to Free Cash Flow
- 18.56
- EV to Operating Cash Flow
- 14.59
Balance Sheet
Duopharma Biotech Bhd. has MYR 255.99M in cash and marketable securities with MYR 471.60M in debt, giving a net cash position of -MYR 215.61M billion.
- Cash & Marketable Securities
- MYR 255.99M
- Total Debt
- MYR 471.60M
- Net Cash
- -MYR 215.61M
- Net Cash Per Share
- -MYR 0.22
- Tangible Book Value Per Share
- MYR 0.78
Margins
Gross margin is 41.27%, with operating margin of 16.60%, and net profit margin of 11.00%.
- Gross Margin
- 41.27%
- Operating Margin
- 16.60%
- Pretax Margin
- 14.45%
- Net Profit Margin
- 11.00%
- EBITDA Margin
- 22.63%
- EBIT Margin
- 17.80%
Analyst Forecast
The average price target for Duopharma Biotech Bhd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 4.79%
- EPS Growth Forecast
- 33.58%
